透明细胞肾细胞癌冷冻消融后111In-girentuximab SPECT随访成像可行
这项前瞻性研究纳入16例接受MR引导下冷冻消融的透明细胞肾细胞癌患者,术前用111In-girentuximab SPECT评估CAIX靶向性,其中10例(63%)术前靶向阳性,9例(56%)可进行术后1个月随访SPECT。9次随访扫描中8次(89%)判为阴性,1次(11%)提示残留 vital 肿瘤,该部位在术后6个月CT出现强化,平均随访21个月(范围1–33)未发现其他残留/复发。结论认为冷冻消融后111In-girentuximab SPECT随访可行,可能有助于早期发现残留或复发。
要点
- 111In-girentuximab SPECT在ccRCC冷冻消融后随访可行,9例中8例阴性。
- 1例术后SPECT阳性者,6个月CT在该部位出现强化提示残留/复发。
- 平均随访21个月(范围1–33)未发现其他残留/复发病例。
核心结论
- 透明细胞肾细胞癌冷冻消融后,使用111In-girentuximab SPECT进行随访成像可行。
- 该成像可能有助于早期发现残留或复发疾病。
研究设计与样本
- 前瞻性研究,16例患者接受111In-girentuximab-SPECT后行MR引导下肾脏冷冻消融。
- 术前SPECT靶向阳性者在冷冻消融后1个月重复SPECT,后续用增强横断面成像随访。
- 标准随访影像方案为术后1、3、6、12、18个月及此后每年行MRI/CT。
主要发现
- 16例中10例(63%)术前111In-girentuximab-SPECT显示肿瘤靶向阳性。
- 10例中9例(56%)符合条件接受术后1个月随访SPECT。
- 9次随访SPECT中8次(89%)判为阴性,1次(11%)显示摄取提示残留 vital 肿瘤。
- 该摄取部位在术后6个月随访CT显示消融区强化,提示残留/复发。
- 平均随访21个月(范围1–33)期间未发现其他残留/复发疾病。
关键数值与推荐
- 术前111In-girentuximab-SPECT肿瘤靶向阳性者才重复术后1个月SPECT。
- 随访SPECT阴性标准为未见提示残留 vital 肿瘤的摄取,9次中8次(89%)为阴性。
- 残留/复发依据增强横断面成像(MRI/CT)上的强化表现判定。
临床怎么用
- 对ccRCC冷冻消融患者,可考虑术前111In-girentuximab-SPECT筛选靶向阳性者。
- 靶向阳性者可在术后1个月行111In-girentuximab-SPECT,辅助早期发现残留或复发。
- SPECT阳性部位应结合增强MRI/CT随访确认。
局限性
- 样本量小,仅16例患者,其中9例接受术后随访SPECT。
- 仅术前靶向阳性者可纳入术后SPECT随访,存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Detection of residual or recurrent vital renal tumor on follow-up (FU) cross-sectional imaging after ablative therapy is challenging. The specific and high expression levels of carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma (ccRCC) makes it a suitable target for imaging using radiolabeled anti-CAIX antibody girentuximab. The objective of this study was to evaluate the feasibility of targeted FU imaging 1 month after cryoablation of ccRCC using single photon emission computed tomography (SPECT) after 111In-labeled girentuximab administration. METHODS: In this prospective study 16 patients underwent 111In-girentuximab-SPECT before MR-guided renal cryoablation between February 2015 and September 2018. In case of tumor targeting 111In-girentuximab-SPECT was repeated 1 month following MR-guided cryoablation. Presence of residual or recurrent vital tumor was assessed on contrast-enhanced cross-sectional imaging during further FU. The standard FU imaging protocol consisted of MRI/CT scans at 1, 3, 6, 12, and 18 months and annually thereafter. RESULTS: A total of 10 (63%) patients showed positive tumor targeting on 111In-girentuximab-SPECT before cryoablation and 9 ( 56%) were eligible to undergo FU SPECT. Of the 9 111In-girentuximab-SPECT FU scans, 8 (89%) were considered negative. One (11%) scan showed uptake suggestive for residual vital tumor. Six months after treatment, FU CT showed contrast enhancement suggestive for residual/recurrent disease in the ablated zone at the site of the 111In-girentuximab uptake after treatment. During a mean FU of 21 months (range 1-33) no other cases with residual/recurrent disease were detected. CONCLUSION: FU imaging with 111In-girentuximab-SPECT is feasible after ccRCC cryoablation and may contribute to early detection of residual or recurrent disease.
引用
- van Oostenbrugge TJ, Langenhuijsen JF, Oosterwijk E, et al. Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab. Eur J Nucl Med Mol Imaging. 2019. PMID: 31768601. doi:10.1007/s00259-019-04613-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。